Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- Sanofi to Shed 200 Jobs in Japan
October 8, 2019
- Chris Hartz to Helm Amicus Japan
October 8, 2019
- Japan Ethical Drug Sales Up 3.0% in August: Crecon
October 8, 2019
- Keytruda Filed for Gastric Cancer in Japan
October 7, 2019
- Keytruda Remains Japan’s Top-Selling Drug in September: Encise
October 7, 2019
- Shionogi, M3 Establish New JV to Provide Disease Solutions by Integrating Physical and Digital Assets
October 7, 2019
- Trader Mitsui’s Iwai Picked for Top Job at Fuji Pharma
October 7, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- Japan IP High Court Favors Chugai in Hemlibra Patent Suit
October 4, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales
October 3, 2019
- SymBio Bags Global Rights to Antiviral Brincidofovir from US Biotech, Aiming to Become Hematology Specialty Pharma
October 3, 2019
- Astellas to Make US$13 Million Investment in Boston Area to Support Startups
October 3, 2019
- Health Canada Accepts Mitsubishi Tanabe’s Plant-Derived Flu Vaccine for Review
October 3, 2019
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…